Garry Watts is to succeed Dr John Brown as non-executive chairman of BTG, an international specialist healthcare company, on 1 January 2012.
Watts is chairman of the Spire Healthcare group of private hospitals. He is also the senior independent director at Stagecoach Group and a non-executive director of Coca-Cola Enterprises.
He was chief executive of SSL International for seven years until its sale in November 2010 to Reckitt Benckiser. He was a member of the supervisory board of the UK's Medicines Healthcare Research Agency for 17 years until 2008 and is a former executive director of Medeva and Celltech. He was also a non-executive director of Protherics until its acquisition by BTG in December 2008.
Louise Makin, chief executive of BTG, commented: ‘On behalf of the board, I'd like to thank John for his enormous contribution to BTG’s development, including his overall stewardship of the business and the support he has given to us all throughout his tenure as chairman.
‘Garry brings a wealth of experience from the healthcare and other sectors that will be of great benefit to BTG and we all look forward to working with him.’
BTG names non-executive chairman
Former chief executive of SSL International joins healthcare firm
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
![2011 nces focus on cancer therapies]()
2011 nces focus on cancer therapies
The future of the pharma industry increasingly lies in drugs for diseases with smaller patient populations, and those targeted more precisely at specific patient sub-populations. Many of the new chemical entities approved in 2011 were targeted at cancer, diabetes and cardiovascular diseases, as well as bacterial and viral infections
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
![What Operation TrialBlazer means for CDMOs and CMC strategy]()
What Operation TrialBlazer means for CDMOs and CMC strategy
The FDA's new framework cuts Phase I data requirements, opens platform manufacturing data reuse and creates a new CRO/CDMO review role as HHS moves to close the gap with China's faster clinical trial pipeline — but how will this affect the pharma sector?
Digital
![Shilpa Biologicals launches PartnerPower real-time visibility platform for biologics CDMO operations]()
Shilpa Biologicals launches PartnerPower real-time visibility platform for biologics CDMO operations
The digital data fabric links R&D, analytical development and GMP manufacturing, replacing periodic reporting with continuous audit-ready transparency aligned to FDA, EMA and PMDA expectations
Manufacturing
![Piramal Pharma Solutions highlights strong performance across more than 200 customer audits]()
Piramal Pharma Solutions highlights strong performance across more than 200 customer audits
Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes
Regulatory
![Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS]()
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS
The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases